JP2010500380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500380A5 JP2010500380A5 JP2009524004A JP2009524004A JP2010500380A5 JP 2010500380 A5 JP2010500380 A5 JP 2010500380A5 JP 2009524004 A JP2009524004 A JP 2009524004A JP 2009524004 A JP2009524004 A JP 2009524004A JP 2010500380 A5 JP2010500380 A5 JP 2010500380A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- ifnα
- optionally
- biological activity
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 37
- 108090001123 antibodies Proteins 0.000 claims 37
- 102000006992 Interferon-alpha Human genes 0.000 claims 13
- 108010047761 Interferon-alpha Proteins 0.000 claims 13
- 230000000694 effects Effects 0.000 claims 11
- 210000004408 Hybridomas Anatomy 0.000 claims 7
- 102000005614 monoclonal antibodies Human genes 0.000 claims 7
- 108010045030 monoclonal antibodies Proteins 0.000 claims 7
- 230000035693 Fab Effects 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 101710026096 ACO2 Proteins 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000000840 anti-viral Effects 0.000 claims 2
- 108091006028 chimera Proteins 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010018651 Graft versus host disease Diseases 0.000 claims 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 claims 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 claims 1
- 206010025135 Lupus erythematosus Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001064 anti-interferon Effects 0.000 claims 1
- 230000003472 neutralizing Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
Claims (16)
任意に、抗体が、少なくとも8つのIFNαタンパク質サブタイプを選択的に中和し、及び、
更に任意に、抗体が、IFNαタンパク質サブタイプA、2、B2、C、F、G、H2、I、J1、K、4a、4b及びWAの生物活性を選択的に中和するが、INFαタンパク質サブタイプD及び1の生物活性は有意には中和しない、
請求項１又は２に記載の抗体。 At least two protein subs wherein the antibody is selected from the group consisting of interferon alpha (“IFNα”) protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA that selectively neutralizes the type of biological activity, at least one biological activity of INFα protein subtypes D did not significantly neutralize the bioactivity, Ri activation or antiviral activity der of the MxA promoter ,
Optionally, the antibody selectively neutralizes at least 8 IFNα protein subtypes, and
Further optionally, the antibody selectively neutralizes the biological activity of IFNα protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but INFα protein The biological activities of subtypes D and 1 are not significantly neutralized,
The antibody according to claim 1 or 2.
a）約300ng/mL未満のIFNαタンパク質サブタイプA、2、B2、C、F、G、H2、I、J1、4a、4b及びWA；及び
b）約375ng/mL未満のIFNαタンパク質サブタイプK。 4. The antibody of any one of claims 1 to 3 , wherein the antibody selectively neutralizes the biological activity of the IFNα protein subtype at a half maximum effective concentration (EC 50 ) selected from the group consisting of:
a) less than about 300 ng / mL of IFNα protein subtypes A, 2, B2, C, F, G, H2, I, J1, 4a, 4b and WA; and
b) IFNα protein subtype K less than about 375 ng / mL.
任意に、抗体が前記生物活性の少なくとも60%を中和し、
更に任意に、抗体が前記生物活性の少なくとも70%を中和し、
更に任意に、抗体が前記生物活性の少なくとも80%を中和し、及び、
更に任意に、抗体が前記生物活性の少なくとも90%を中和する、
請求項1から４のいずれかに記載の抗体。 Antibody, the IFNα neutralize at least 50% of the subtypes of bioactivity, the bioactivity Ri activation der of the MxA promoter,
Optionally, the antibody neutralizes at least 60% of the biological activity,
Further optionally, the antibody neutralizes at least 70% of the biological activity,
Further optionally, the antibody neutralizes at least 80% of the biological activity, and
Further optionally, the antibody neutralizes at least 90% of the biological activity,
The antibody according to any one of claims 1 to 4 .
任意に、抗体がモノクローナル抗体である、
請求項1から６のいずれかに記載の抗体。 Antibody, Ri mouse antibodies, human antibodies, humanized antibodies, chimeric antibodies or antibody fragments der, and,
Optionally, the antibody is a monoclonal antibody,
The antibody according to any one of claims 1 to 6 .
任意に、抗体がモノクローナル抗体ACO-2である、
請求項７に記載の抗体。 Antibody, only including humanized or chimeric form of monoclonal antibody ACO-2, or,
Optionally, the antibody is monoclonal antibody ACO-2,
The antibody according to claim 7 .
任意に、抗体フラグメントが、Fab、Fab'、F(ab') 2 、Fv又はscFvフラグメントを含む、
請求項1から８のいずれかに記載の抗体。 Antibody Ri antibody fragments der,
Optionally, the antibody fragment comprises a Fab, Fab ′, F (ab ′) 2 , Fv or scFv fragment,
The antibody according to any one of claims 1 to 8 .
任意に、抗体フラグメントが、Fab、Fab'、F(ab') 2 、Fv又はscFvフラグメントを含む、
前記抗体フラグメント。 An antibody fragment of the monoclonal antibody according to claim 10 or 11 ,
Optionally, the antibody fragment comprises a Fab, Fab ′, F (ab ′) 2 , Fv or scFv fragment,
Said antibody fragment .
任意に、宿主細胞がハイブリドーマである、
前記宿主細胞。 A host cell comprising a nucleic acid encoding the antibody of any of claims 1 to 12,
Optionally, the host cell is a hybridoma,
Said host cell .
任意に、ハイブリドーマが、ATCCアクセッション番号PTA-7778を有する、
前記ハイブリドーマ。 A hybridoma producing the monoclonal antibody ACO-2 ,
Optionally, the hybridoma has ATCC accession number PTA-7778.
Said hybridoma .
請求項1から１２のいずれかに記載の抗体の有効量を含み、
前記生物活性がMxAプロモーターの活性化又は抗ウイルス活性である、
前記医薬組成物。 Diseases associated with abnormal expression of at least one IFNα protein subtype selected from the group consisting of IFNα protein subtype A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA Or a pharmaceutical composition for treating a symptom in a subject without neutralizing the biological activity of IFNα protein subtype D,
Comprising an effective amount of the antibody of any one of claims 1 to 12 ,
The biological activity is activation of MxA promoter or antiviral activity;
Said pharmaceutical composition .
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83659906P | 2006-08-09 | 2006-08-09 | |
| US60/836,599 | 2006-08-09 | ||
| PCT/US2007/075616 WO2008021976A2 (en) | 2006-08-09 | 2007-08-09 | Anti-interferon alpha monoclonal antibodies and methods for use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500380A JP2010500380A (en) | 2010-01-07 |
| JP2010500380A5 true JP2010500380A5 (en) | 2010-09-24 |
| JP5230022B2 JP5230022B2 (en) | 2013-07-10 |
Family
ID=39082973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524004A Active JP5230022B2 (en) | 2006-08-09 | 2007-08-09 | Anti-interferon alpha monoclonal antibody and method of use |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2057190A4 (en) |
| JP (1) | JP5230022B2 (en) |
| WO (1) | WO2008021976A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2597265C (en) | 2005-02-10 | 2015-03-24 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| CN101678100A (en) * | 2006-12-06 | 2010-03-24 | 米迪缪尼有限公司 | methods of treating systemic lupus erythematosus |
| JP2010512313A (en) * | 2006-12-06 | 2010-04-22 | メディミューン，エルエルシー | Treatment of systemic lupus erythematosus |
| MX2010012052A (en) | 2008-05-07 | 2010-12-14 | Novo Nordisk As | Humanized antibodies against human interferon-alpha. |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CN106589122B (en) * | 2015-10-20 | 2020-10-27 | 中国人民解放军军事医学科学院生物工程研究所 | Human anti-human multi-subtype interferon alpha antibody and application thereof |
| EP3765069A1 (en) | 2018-03-16 | 2021-01-20 | Zoetis Services LLC | Peptide vaccines against interleukin-31 |
| JP7449234B2 (en) | 2018-03-16 | 2024-03-13 | ゾエティス・サービシーズ・エルエルシー | Interleukin 31 monoclonal antibody for veterinary use |
| RU2737466C1 (en) * | 2019-12-30 | 2020-11-30 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Humanised neutralizing antibody to human interferon-beta |
| CN112129952B (en) * | 2020-09-21 | 2023-06-06 | 普健生物（武汉）科技有限公司 | Chemiluminescent kit for detecting human soluble CD14 |
| CN116284368A (en) * | 2022-06-15 | 2023-06-23 | 重庆艾生斯生物工程有限公司 | Anti-human MxA antibodies or antigen-binding portions thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| CA2597265C (en) * | 2005-02-10 | 2015-03-24 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
-
2007
- 2007-08-09 JP JP2009524004A patent/JP5230022B2/en active Active
- 2007-08-09 WO PCT/US2007/075616 patent/WO2008021976A2/en active Search and Examination
- 2007-08-09 EP EP07840833A patent/EP2057190A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010500380A5 (en) | ||
| JP2014111644A5 (en) | ||
| JP2008529529A5 (en) | ||
| JP2012012402A5 (en) | ||
| RU2007133608A (en) | MONOCLONAL ANTIBODIES AGAINST INTERFERON-ALPHA AND METHODS OF APPLICATION | |
| JP2009502171A5 (en) | ||
| JP2011520898A5 (en) | ||
| NZ616992A (en) | Anti-ilt7 antibody | |
| JP2018519364A5 (en) | ||
| RU2010149746A (en) | CROSS-REACTIVE ANTIBODIES ANTI-IL-17A / IL-17F AND WAYS OF THEIR APPLICATION | |
| JP2015535820A5 (en) | ||
| JP2011509245A5 (en) | ||
| JP2016135783A5 (en) | ||
| JP2008508864A5 (en) | ||
| JP2007514419A5 (en) | ||
| RU2006124611A (en) | Antibodies against IP-10 (VARIANTS) AND METHOD OF PRODUCTION THEREOF, immunoconjugates and bispecific molecules BASED THEREON AND THEIR COMPOSITIONS, METHOD OF TREATMENT (OPTIONS), encodes a molecule NK appropriate expression vector, host cell, a transgenic mouse and the hybridomas | |
| JP2010538608A5 (en) | ||
| JP2007262074A5 (en) | ||
| JP2008529497A5 (en) | ||
| JP2016093195A (en) | Neutralizing anti-ccl20 antibodies | |
| JP2010526028A5 (en) | ||
| RU2011145428A (en) | ANTIBODIES AGAINST TNF-α AND THEIR APPLICATION | |
| JP2011514150A5 (en) | ||
| NZ621483A (en) | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r | |
| JP2005515963A5 (en) |